Therapeutic drug monitoring (TDM) of biologics is a rapidly evolving field. We aimed to
provide a consensus statement regarding the clinical utility of TDM for biologics in …

Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …

Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

Background & Aims Ustekinumab is a monoclonal antibody that binds with high affinity to the
p40 subunit of human interleukin 12 (IL12 and IL23) that has been approved for treatment of …

Abstract Background and Aims We sought to analyze whether response to a second-line
biologic varies depending on the reason for discontinuation of the primary anti-TNF agent …

Abstract Background and Aims Ustekinumab is approved for the treatment of Crohn's
disease [CD]. Systematically registered prospective real-world data are scarce. We therefore …

Im Jahr 2019 wurden etwa 25 500 Patient* innen mit M. Crohn im Krankenhaus stationär
behandelt [1]. Meistens tritt die Erkrankung in der Adoleszenz und im jungen …

The advent of anti-TNF agents has dramatically changed the treatment algorithms for IBD in
the last 15 years, but primarily and more importantly secondary loss of response is often …

Abstract Model-informed precision dosing (MIPD) stands as a significant development in
personalized medicine to tailor drug dosing to individual patient characteristics. MIPD moves …

Background Large real-world-evidence studies are required to confirm the durability of
response, effectiveness, and safety of ustekinumab in Crohn's disease (CD) patients in real …